Table 2.

Screening positivity rates by type of epileptic seizure and estimated lifetime epilepsy prevalences by scenario and type of seizure.

	n	Type of epileptic seizure
		generalized		focal		unspecified		any type
		n	%	n	%	n	%	n	%
Both sexes	49,697	293	0.60 [0.53–0.67]	986	2.02 [1.90–2.15]	32	0.07 [0.04–0.09]	1085	2.23 [2.10–2.36]
scenario 1			0.27 [0.18–0.36]		2.14 [1.98–2.31]		NA †		2.41 [2.24–2.59]
scenario 2			0.43 [0.37–0.49]		1.45 [1.34–1.55]		0.05 [0.03–0.07]		1.59 [1.48–1.70]
Females	25,689	151	0.60 [0.51–0.70]	613	2.43 [2.24–2.63]	24	0.10 [0.06–0.14]	671	2.66 [2.46–2.86]
scenario 1			0.26 [0.14–0.40]		2.67 [2.43–2.93]		NA †		2.98 [2.72–3.25]
scenario 2			0.43 [0.35–0.51]		1.74 [1.58–1.90]		0.07 [0.04–0.1]		1.91 [1.74–2.07]
Males	24,008	142	0.60 [0.51–0.71]	373	1.59 [1.43–1.74]	8	0.03 [0.01–0.07]	414	1.76 [1.60–1.94]
scenario 1			0.27 [0.14–0.41]		1.54 [1.34–1.76]		NA †		1.80 [1.58–2.03]
scenario 2			0.43 [0.35–0.51]		1.13 [1.00–1.27]		0.02 [0.00–0.04]		1.26 [1.12–1.40]

Adjusting for inaccuracy of screening questionnaire using Bayesian statistics.

Scenario 1: sensitivity 76.3%, specificity 99.6%.

Scenario 2: positive predictive value 73%, negative predictive value 100%.

† Bayesian analysis yielded negative results.